Experimental donor CAR-T therapy tested in lymphoma – trial halted early
NCT ID NCT06256484
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a new therapy called ATA3219, which uses immune cells from a healthy donor to attack cancer cells in people with relapsed or refractory B-cell non-Hodgkin lymphoma. The study aimed to check safety and see if the treatment works, but it was stopped early after enrolling only one participant. Because the trial was so small, we cannot draw any conclusions about how well this therapy might work.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ATA3219 (a type of immune cell therapy called CAR-T, made from donor cells)
What this could lead to
If it works, this could offer a new treatment option for people with hard-to-treat B-cell lymphoma who have run out of standard therapies.
What could go wrong
This was a very early, small Phase 1 trial that was terminated after enrolling only 1 person, so we have very little data. The therapy may cause serious side effects like cytokine release syndrome or nervous system problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AdventHealth Cancer Institute
Orlando, Florida, 32804, United States
-
Fiona Stanley Hospital
Murdoch, Western Australia, 6150, Australia
-
Norton Cancer Institute - Saint Matthews
Louisville, Kentucky, 40207, United States
-
Princess Alexandra Hospital
Woolloongabba, Queensland, 4102, Australia
-
Sidney Kimmel Cancer Center - Jefferson Health
Philadelphia, Pennsylvania, 19107, United States
-
University of Virgina
Charlottesville, Virginia, 22908, United States